STOCKS TELEGRAPH

Tag: CAPR Stock

  • Pre-Hour Trading Sees Capricor (CAPR) Stock Climb Amid FDA Approval Progress

    Pre-Hour Trading Sees Capricor (CAPR) Stock Climb Amid FDA Approval Progress

    After a major regulatory breakthrough, Capricor Therapeutics, Inc. (NASDAQ: CAPR) stock value has significantly increased. CAPR shares have increased 10.46% to $15.10 as of the most recent premarket check, indicating that investors were optimistic about the company’s recent developments.

    FDA Accepts Biologics License Application

    The U.S. Food and Drug Administration (FDA) has accepted Capricor’s Biologics License Application (BLA) for deramiocel, an investigational cell therapy that targets the cardiomyopathy associated with Duchenne muscular dystrophy (DMD), for review. This is a big step in the direction of the therapy’s potential full approval.

    Additionally, the FDA granted the application Priority Review, setting August 31, 2025, as the target action date under the Prescription Drug User Fee Act (PDUFA). As of now, the FDA has not discovered any issues that would prolong the review procedure.

    Potential Progress in DMD-Cardiomyopathy Management

    Capricor is one step closer to creating a revolutionary treatment for DMD-cardiomyopathy, a condition for which there are currently no approved therapies, thanks to the BLA’s acceptance. With the potential for broad use throughout the DMD-cardiomyopathy therapy landscape, deramiocel is anticipated to be a quarterly, lifetime medication if authorized.

    Clinical data from Capricor’s Phase 2 HOPE-2 and HOPE-2 Open Label Extension (OLE) studies, which have shown encouraging results when compared to an FDA-funded dataset on the development of DMD cardiomyopathy, support the application.

    Regulatory Labels Boost the Chance of Approval

    One of the main causes of death for DMD patients, DMD-cardiomyopathy, has been effectively mitigated with deramiocel. The possible approval of this medicine might mark a major improvement in available treatment alternatives due to the encouraging safety and effectiveness evidence. Deramiocel’s potential to enhance patient outcomes is highlighted by its FDA Priority Review status.

    Further highlighting the therapy’s significance is the fact that it has been designated an Orphan Drug by the European Medicines Agency (EMA) and the FDA. Capricor’s RMAT (Regenerative Medicine Advanced Therapy) and ATMP (Advanced Therapy Medicinal Product) designations in the US and Europe, respectively, support its regulatory approach.

    Additionally, because of its prior categorization as a rare pediatric condition, Capricor may be eligible for a Priority Review Voucher (PRV) if the FDA approves commercialization by September 30, 2026.

  • Pre-Market Trading Boosts Capricor Therapeutics (CAPR) Shares

    Pre-Market Trading Boosts Capricor Therapeutics (CAPR) Shares

    Due to a recent licensing decision, Capricor Therapeutics, Inc.’s (NASDAQ: CAPR) stock value has been dramatically on the US stock charts today. As of the latest pre-market check, CAPR shares were up 8.75% at $18.64. The main cause of this rise in stock price is Capricor’s announcement of a significant development in its regulatory process with the US Food and Drug Administration (FDA).

    Capricor Commenced Licensing Process

    Capricor (CAPR) has formally started the FDA’s rolling submission procedure for a biologics license application (BLA), in an effort to get its flagship medication, deramiocel, approved. Deramiocel is intended to treat cardiomyopathy in individuals with Duchenne muscular dystrophy (DMD), a debilitating illness for whom there are presently no recognized therapies.

    This action represents a significant turning point in Capricor’s pursuit of complete FDA clearance, which would allow the business to provide patients in need with this cutting-edge medication.

    Possibility of Priority Evaluation and Quick Approval

    Capricor aims to complete its BLA submission by the end of 2024. Given the potential impact of deramiocel on the safety and effectiveness of DMD cardiomyopathy treatment, the application may qualify for priority review. Should the FDA grant this status, it could significantly expedite the approval process, enabling faster access to this first-in-class therapy for DMD patients.

    CAPR Presenting Long-term Data at WMS 2024

    In parallel with its regulatory advancements, Capricor has been showcasing the long-term safety and efficacy data from its HOPE-2 open-label extension (OLE) study at the 29th Annual Congress of the World Muscle Society (WMS 2024) in Prague. This data underscores the multi-faceted benefits of deramiocel and has reinforced the company’s recent decision to move forward with the BLA submission.

    The presentation at WMS highlights the foundational results supporting deramiocel’s long-term impact, strengthening Capricor’s (CAPR) position as a leader in innovative therapies for rare diseases like DMD.

  • Capricor (CAPR) Sees Stock Rise After Announcing BLA Submission Plans

    Capricor (CAPR) Sees Stock Rise After Announcing BLA Submission Plans

    The stock of Capricor Therapeutics, Inc. (NASDAQ: CAPR) is rising significantly on the charts right now. Following the company’s announcement of plans to submit a Biologics License Application (BLA), shares of CAPR were up 39.03% to $8.30 as of the most recent market check. This action represents a significant step toward the approval of its main medication, deramiocel, for the management of cardiomyopathy associated with Duchenne muscular dystrophy (DMD).

    Capricor Plans for Biologics License Application

    Capricor disclosed its intent to submit a BLA based on promising cardiac data and natural history studies. After many meetings with the Food and Drug Administration (FDA) in the United States, the business plans to submit a BLA by October 2024, and by the end of the year, the complete application is anticipated.

    CAPR Expanding the Treatment Scope

    Apart from pursuing approval for managing cardiomyopathy associated with DMD, Capricor intends to conduct post-approval investigations to broaden the drug’s indication to include skeletal muscle myopathy. Data from Cohorts A and B of the company’s current Phase 3 HOPE-3 study will be used. Notably, Capricor has chosen to forgo unblinding Cohort A, which was initially planned for the fourth quarter of 2024, in order to maintain the integrity of the trial for upcoming analysis.

    Addressing an Unmet Medical Need

    As of right now, DMD cardiomyopathy—the primary cause of mortality for those with Duchenne muscular dystrophy—has no FDA-approved treatments. The FDA’s dedication to developing treatments for uncommon diseases and the compelling clinical evidence demonstrating deramiocel’s efficacy support the company’s application for approval. There is optimism for a much-needed therapy since the medicine has shown in many studies to be able to decrease heart degeneration.

    Regulatory Support and Path Forward

    Deramiocel holds FDA Orphan Drug Designation and is further supported by the RMAT (Regenerative Medicine Advanced Therapy) designation. If approved, Capricor could also secure a Priority Review Voucher (PRV), owing to its rare pediatric disease designation. These developments position the company to expedite deramiocel’s path to market, potentially offering a groundbreaking treatment to DMD patients.

  • Here’s the Reason Why Capricor Therapeutics, Inc. (CAPR) Stock is Roaring in the Premarket

    Capricor Therapeutics, Inc. (CAPR) is a biopharmaceutical company engaged in the development of therapeutics for treating an array of diseases. The company’s pipeline product candidate includes CAP-1002 used for treating Duchenne muscular dystrophy and the cytokine storm in COVID-19 patients. The Company is also developing exosomes capable of delivering nucleic acids to treat different diseases.

    The price of CAPR stock during the regular trading on January 24, 2022 was $2.83 with a decline of 2.08%. At last check in the premarket on January 25, 2022, the stock was significantly up by 7.42%.

    CAPR: Events and Happenings

    On January 25, 2022, CAPR reported about its entry into strategic collaboration with Japanese origin Nippon Shinyaku Company. The basic aim of the partnership is the commercialization and distribution of CAP-1002 in the US. On December 13, 2021, CAPR reported its vaccine and developmental portfolio updates mainly focusing on COVID-19. Company’s pre-clinical exosome mRNA vaccine has the capability for a strong T-cell response in a viral infection. In addition, the company will also report topline results from its INSPIRE Phase 2 studies in Q1 2022.

    On November 12, 2021, CAPR reported that the company’s Executives presented at the Virtual TriLink Biotechnologies Annual mRNA Day Conference held on November 16, 2021.

    CAPR: Key Financials

    On November 09, 2021, CAPR announced its financial results for the third quarter ended September 30, 2021. Some of the key updates are as follows.

    Net Loss per Share

    Basic and diluted net loss per share in Q3 2021 was $3.9 million, or $0.17 compared to $3.9 million, or $0.20 for the same period in 2020.

    Assets

    Total assets in Q3 2021 were recorded to be $43.1 million.

    On September 24, 2021, CAPR reported optimistic final results for its HOPE-2 clinical studies utilizing CAP-1002. On September 22, 2021, CAPR reported that the company’s Executives presented at the conferences namely Virtual Cantor Fitzgerald Global healthcare Conference held on September 30 and Cell & Gene Meeting on the Mesa held on October 13, 2021.

    Conclusion

    CAPR stock is 40% down compared to the last six months period due to the challenges faced by the economy because of the worsening pandemic situation. The current premarket increase in stock price is the consequence of the company’s announcement of its entry into a strategic partnership. The analysts are confident that the current market scenario is favorable for the company’s stock to bloom.